With the legalization of medical marijuana use among adults in Canada in 2018, the crypto currency stock exchange has been overshadowed by the pot stocks craze. As cannabis is becoming more and more acceptable throughout the world the big names in the pot industry are trying to get ahead of the game and get everything ready for the next big steps. These are the companies you want to follow closely and consider investing in. While there are about 6 big names on pot market right now, there are some that really stand out, among them is GW Pharmaceuticals.
GW Pharmaceuticals Plc is a biopharmaceutical company, whose main goal is the discovery, development, and commercialization of novel therapeutics. The company is focused on offering leading cannabinoid products like Epidolex oral solution CV that treats seizures associated with tuberous sclerosis complex. The drug was launched in the US as a prescription medicine by their US operating subsidiary, Greenwich Biosciences Inc., on November 1, 2018.
“This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies,” said FDA Commissioner Scott Gottlieb. (Source: “US approves first marijuana plant-derived drug,” Reuters, June 25, 2018.)
GW is also expecting a decision on a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in early 2019.
The company was founded by Geoffrey William Guy and Brian Whittle in 1998. Compared to other big Canadian pot players, GW Pharmaceuticals is headquartered in Cambridge, the United Kingdom. The company is listed on the NASDAQ Global Market (GWPH) and has operations in both the US and the UK.
What helped GW become a leading cannabis company is its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise. They were basically the first to successfully develop the world’s first prescription medicine derived from the marijuana plant, called Sativex® (delta-9-tetrahydrocannibinol and cannabidiol in the EU; nabiximols in the US). Nowadays, the drug is approved in more than 25 countries for treatment of spasticity due to multiple sclerosis.
GW is strongly focused on creating innovative cannabinoid-based prescription medicines to patients with various needs and truly making a difference. By creating cost-effective products, GW seeks to maximize the value of its product development opportunities and shareholder returns.
Besides a huge in-house team of scientists, GW partners with a lot of impressive international scientists in the cannabinoid field.
Prescription pharmaceutical products manufactured by GW Pharmaceuticals meet the stringent cGMP requirements of the U.S. FDA and other global regulatory authorities. Now that you know what and how the company does, let’s look into their number and see if it is worth investing in GW Pharmaceuticals in 2019.
Currently, the GW pharmaceuticals stock price is 129.710 USD today. It is highly probable that the stock price will go up as high as 146 USD in one year. By 2024, the stock price can go up as high as 229.288 USD. So, investing in GW Pharmaceuticals today would bring you a profit of 12.70% by the next year. The chances of GW stock price dropping are pretty minimal.
What sets GW Pharmaceuticals apart from other big names in the pot industry is that it is more of a pharmaceutical company than simply a cannabis producer that is trying to get into medical business. This gives the company more credibility, more stability and greater opportunities. The numbers say the same. Revenue for GW Pharmaceuticals for the nine months showed a huge bump from £6.1 million of prior 9-month period to this year’s £10.7 million ($14.2 million). (Source: “GW Pharmaceuticals plc Reports Fiscal Third Quarter 2018 Financial Results and Operational Progress,” GW Pharmaceuticals PLC, August 7, 2018.)
GW Pharmaceuticals stock has kept improving their numbers since the results came in in early August.
The fact that GW Pharmaceuticals is in between marijuana and pharma industry is both good for the investors and a little cautious. The reason for this is that it has to compete on two very different markets simultaneously, a newly emerging one and a slow, taxing regulatory process that can sometimes end in total defeat.
During the 2018 cannabis stock price boom, GW Pharmaceuticals didn’t see as big of a rise as the other stock companies. Its stock prices increased by 12%, while most of the other cannabis companies saw a 50% growth. However, this also means that GW is on a stable path and less likely to see a massive fall.
So, if a long term profit and a safe investment is what you are looking for, then GW Pharmaceuticals might be your cup of tea. The fact is that the company has already taken important steps to revolutionizing the medical industry forever by introducing cannabis based drugs to the official market.